|
業務類別
|
Biotechnology |
|
業務概覽
|
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer. |
| 公司地址
| 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 388-5600 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.oricpharma.com |
| 員工數量
| 104 |
| Mr. Dominic G. Piscitelli |
Chief Financial Officer and Principal Accounting Officer |
美元 458.08K |
23/02/2026 |
| Mr. Matthew Panuwat |
Chief Business Officer |
-- |
23/04/2025 |
| Dr. Pratik S. Multani, M.D. |
Chief Medical Officer |
美元 493.58K |
23/04/2025 |
| Mr. Jacob M. Chacko, M.B.A.,M.D. |
President, Chief Executive Officer and Director |
美元 627.33K |
23/02/2026 |
|
|
| Dr. Angie You, PhD |
Independent Director |
23/02/2026 |
| Dr. Richard Heyman, PhD |
Chairman of the Board |
23/02/2026 |
| Ms. Mardi C. Dier |
Independent Director |
23/02/2026 |
| Dr. Lori Anne Kunkel, M.D. |
Independent Director |
23/02/2026 |
| Mr. Stephen L. Hoerter |
Independent Director |
23/02/2026 |
| Mr. Jacob M. Chacko, M.B.A.,M.D. |
President, Chief Executive Officer and Director |
23/02/2026 |
|
|
|
|
